Work

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.4567

Authors: W. M. Stadler, D. J. Vaughn, G. Sonpavde, N. J. Vogelzang, S. T. Tagawa, D. P. Petrylak, P. J. Rosen, C. Lin, J. F. Mahoney, S. S. Modi, P. Lee, M. S. Ernstoff, W. Su, A. I. Spira, M. Ould Kaci, T. Taube, R. Vinisko, C. Schloss, C. Zhao, M. A. Carducci

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2244641473

Cites:

Cited by: 7

Related to: 10